Skip to main content

Biomedical Research Legislation

This page provides summaries of legislation proposed in the 117th Congress affecting biomedical research policy. This page will be updated as relevant legislation is introduced.

Advanced Research Project Agency–Health Act (H.R.5585)

  • This legislation would establish ARPA-H, to coordinate with the NIH on “high-need cures”, defined as a “drug, biological product, or device (A) that should be prioritized to detect, diagnose, mitigate, prevent, or treat any disease or medical condition; and (B) for which incentives in commercial market are unlikely to result in the adequate or timely development of such drug, biological project, or device”.

American Cures Act (S.962)

  • The bill would provide annual budget increases of five percent plus inflation at America’s top four biomedical research agencies: the National Institutes of Health, the Centers for Disease Control and Prevention, the Department of Defense Health Program, and the Veterans Medical and Prosthetics Research Program.

Cures 2.0 Act (H.R. 6000)

  • The legislation would establish ARPA-H within NIH, make certain telehealth expansions permanent, give recommendations for decentralizing clinical trials, provide support for research interrupted by COVID-19, aim to increase diversity in clinical trials and expand access to breakthrough therapies, and expand access to genetics-based testing, among other provisions.

Diverse and Equitable Participation in Clinical Trials (DEPICT) Act (H.R.6584)

  • This legislation would require improved reporting standards for clinical trials and boost resources, such as workshops and community health center grants, to improve access to clinical trials in underrepresented communities. 

DIVERSE Trials Act (H.R. 5030)

  • The legislation aims to improve diversity in clinical trials and data collection for COVID-19 and future public health threats to address social determinants of health.

Gabriella Miller Kids First Research Act 2.0 (H.R. 623 & S.1521)

  • The bill would require certain civil penalties collected from pharmaceutical, cosmetic, supplement, and medical device companies to be transferred to a fund at NIH for the Gabriella Miller Kids First Pediatric Research Program.

National Biomedical Research Act (H.R.4124)

  • This legislation would establish a Biomedical Innovation Fund at the NIH and the FDA to support research for disease prevention, diagnosis, and treatment, including research for diseases that disproportionally account for federal health care spending. 

Pediatricians Accelerate Childhood Therapies (PACT) Act of 2021 (S.1357)   

  • The bill would require NIH to make awards to support early-career pediatric researchers, as well as provide statutory authority for the Trans-NIH Pediatric Research Consortium to coordinate pediatric research across national health research institutions. 

Research Investment to Spark the Economy (RISE) Act (S.289 & H.R.869)

  • This legislation would authorize nearly $25 billion in emergency relief funds for federal science agencies, including $10 billion for the NIH.
  • Updated: